Glenmark Pharmaceuticals on Friday reported 11% year-on-year (YoY) rise in adjusted net profit for the fourth quarter of FY25, driven by strong performance in Europe and improved operating margins. The company also reaffirmed its focus on innovation-led growth and global expansion heading into FY26.
Adjusted net profit for Q4FY25 stood at ₹347 crore, with a PAT margin of 10.6%, up from ₹312 crore a year earlier. Revenue rose 6.3% YoY to ₹3256 crore, while EBITDA grew 11.2% to ₹560.7 crore, with margins improving to 17.2%.
“Our performance reflects the underlying resilience of our business and the strength of our diversified portfolio,” said Glenn Saldanha, Chairman & MD. “We are committed to building on this momentum in FY26, with a sharper focus on innovation and global scale.”
Europe emerged as the top-performing region, while North America saw a decline due to pricing pressure in generics and India remained flat.
Europe leads 20% YoY to ₹733.5 crore in Q4FY25, while US declined 5.4% YoY to ₹714.6 crore during the same period. India rose 0.4% YoY to ₹943 crore. Rest of the world (RoW) grew 5% to ₹790 crore.
For the full year, Glenmark reported adjusted PAT growth of 10.4% to ₹1389.4 crore, revenue rose 12.8% YoY to ₹13,321.7 crore. EBITDA almost doubled ₹2351 crore with EBITDA margin at 17.6%.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
